Fig. 2

Knocking down LAMP5-AS1 suppress MLL fusion protein expression and infiltration of MLL leukemia in vivo. (a) Wright-Giemsa staining of bone marrow of mouse recipients of PBS, sh-NC cells or sh-LAMP5-AS1 MV4-11 cells. MV4-11 cells were indicated by the red arrows. Scale bars, 50 μm. (b) Representative flow cytometry graphs showing the blasts in organ samples from mice treated with sh-NC or sh-LAMP5-AS1 knockdown MV4-11 cells. Mice treated with PBS were used as the negative controls. (c) Histogram plots show the statistical values for (b) Error bars reflect ± SEM (**, p < 0.01, ***, p < 0.001). d Kaplan–Meier curves show the survival of mice intravenously injected with sh-NC and sh-LAMP5-AS1 MV4-11 cells (***, p < 0.001). Following subcutaneous inoculation of shRNA-transformed MOLM-13 cells into the flanks of NOD-SCID mice, LAMP5-AS1 knockdown inhibited the malignant proliferation of MLL leukemia cells and subsequent tumor size (e), growth (f), and weight (g) in vivo. Error bars reflect ± SEM (ten mice per group, **, p < 0.01; ***, p < 0.001). (h) MLL-AF9 protein levels dramatically decreased in LAMP5-AS1-knockdown MOM-13 cell-transfected NOD/SCID mice. The MLL-AF9/ Tubulin densitometric ratio was recorded by ImageJ